In inflammatory bowel disease (IBD), inflammation is sustained by an exaggerated response of lymphocytes. This results from enhanced expression of anti-apoptotic B cell lymphoma (BCL-2) and BCL-XL associated with a diminished turnover. Azathioprine (AZA) directly targets BCL-2 family-mediated apoptosis. We investigated whether the BCL-2 family expression pattern could be used to predict treatment response to AZA and determined whether BCL-2 inhibitor A-1211212 effectively diminishes lymphocytes and ameliorates inflammation in a model of colitis. BCL-2 family expression pattern was determined by next-generation sequencing (NGS). BCL-2 inhibitor was administered orally to Il10 -/-mice. Haematological analyses were performed with an ADVIA 2120 and changes in immune cells were investigated using quantitative polymerase chain reaction (qPCR) and fluorescence activated cell sorter (FACS). We determined similar expression levels of BCL-2 family members in patients with remission and patients refractory to treatment, showing that BCL-2 family expression can not predict AZA treatment response. Expression was not correlated with the modified Truelove and Witts activity index (MTWAI). BCL-2 inhibitor initiated cell death in T cells from patients refractory to AZA and reduced lymphocyte count in Il10 -/-mice. FACS revealed diminished CD8 + T cells upon BCL-2 inhibitor in Il10 -/-mice without influencing platelets. Tnf, Il1β, Ifn and Mcp-1 were decreased upon BCL-2 inhibitor. A-1211212 positively altered the colonic mucosa and ameliorated inflammation in mice. Pro-apoptotic BCL-2 inhibitor A-1211212 diminishes lymphocytes and ameliorates colitis in Il10 -/-mice without inducing thrombocytopenia. BCL-2 inhibition could be a new therapy option for patients refractory to AZA.
Introduction
Inflammatory bowel disease (IBD) affects approximately one in 150 people in the industrialized world. IBD is characterized by a chronic inflammation of the intestinal wall and comprises two main conditions, ulcerative colitis (UC) and Crohn's disease (CD). The inflammatory state in IBD is sustained by an exaggerated response of T lymphocytes to luminal antigens, which is associated with an increased resistance to apoptosis in these cells [1] . The B cell lymphoma (BCL)-2 family plays a critical role in the control of immune responses by regulating the expansion and contraction of the activated lymphocyte population via apoptosis. Pro-survival BCL-2 family members [BCL-2, BCL-XL, BCL-ω, myeloid leukaemia cell differentiation protein 1 (MCL-1) and BCL-related protein A1 (A1)] interact with pro-apoptotic BCL-2 family members [e.g. BAX and BAK from the BAX group, and BH3-only protein (BIM) and B cell lymphoma 2 modifying factor (BMF) from the BH3-only group], and induce or abolish apoptosis. All BCL-2 family members share a those patients with a specific chromosomal abnormality. However, neutropenia has been reported as a side effect. A-1211212 (a close analogue of venetoclax) is a BCL-2 selective orally bioavailable inhibitor. Pro-apoptotic A-1211212 reduces the number of neutrophils in the circulation of rats without influencing the platelet counts [21] .
BH3 mimetics that antagonize BCL-2 family proteins were developed initially for the treatment of cancer, while exhibiting minimal toxicity toward normal cells. Additionally, a number of studies demonstrate that the BCL-2 inhibitor ABT-737 is also able to enhance apoptosis in proinflammatory/autoreactive lymphocytes escaping the physiological termination of their life cycle. Thus, ABT-737 is effective in treating animal models of autoimmune diseases [22] , arthritis [23] and lupus [24] . Furthermore, expression of the pro-apoptotic BIM, and the extent of its association with BCL-2, correlates with in vivo ABT-737 sensitivity [25] . Recently, we showed that ABT-737 limits the persistence of lymphocytes in a mouse model of colitis [26] . However, the amelioration of colitis was accompanied by lymphopenia.
In this study, we have shown that the expression pattern of BCL-2 family proteins does not predict the response to AZA treatment in IBD. Nonetheless, inhibition of BCL-2 initiated cell death in CD4 + T cells from patients refractory to AZA. We also found that the BCL-2 inhibitor A-1211212 effectively diminished accumulated lymphocytes and ameliorated colitis without inducing thrombocytopenia in a murine model of spontaneous colitis. Regulating inappropriate survival of autoreactive lymphocytes through the inhibition of BCL-2 may provide a new therapeutic strategy in IBD.
Materials and methods

Ethical considerations
We retrieved data from 48 patients (Supporting information, Table S1 ) from the SIBDCS, a longitudinal, prospective, cohort study of Swiss residents diagnosed with IBD 27 approved by the local ethical committees (EK-1316). Animal experiments were approved by the Cantonal Comission for Animal Experiments (160/2014).
Next-generation sequencing (NGS)
Blood samples were collected from three patients with sustained remission following AZA treatment and three patients refractory to treatment (Supporting information, Table S1 ). NGS was performed using total RNA that passed Tapestation (Agilent Technologies, Santa Clara, CA, USA) quality control with a RNA integrity number (RIN) > 8·3 (Supporting information, Fig. S1 ). Illumina NGS was performed by the Functional Genomics Center Zurich.
Isolation and stimulation of human CD4 + T cells from whole blood
Blood samples were collected before and after treatment with AZA from 27 patients with sustained remission following AZA treatment, 21 patients refractory to treatment and eight healthy controls without treatment (Supporting information, Table S1 ). Peripheral blood lymphocytes (PBLs) were isolated using Ficoll (Histopaque-1077, 10771-100ML; Sigma, St Louis, MO, USA) and resuspended in medium: RPMI-1640 (21875-034; Gibco, Carlsbad, CA, USA), 2 mM L-glutamine, 100 U/ml each of penicillin and streptomycin, 50 mM β-mercaptoethanol and 10% fetal calf serum (FCS). CD4 + T cells were isolated using the Cell Isolation Kit (130-096-533; Miltenyi Biotech, Bergisch Gladbach, Germany). For stimulation of CD4 + T cells, a well plate was coated 24 h before the experiment with anti-CD3 (0·04 µg/ml, 130-093-387; Miltenyi Biotech). CD4 + T cells were cultivated (37 °C, 5 % CO 2 
Flow cytometry and mass cytometry
Apoptotic cells were determined by annexin V (ALX-209-252-T100; Enzo Life Sciences, Farmingdale, NY, USA) and propidium iodide (PI, P4864; Sigma) staining. Annexin V -/PI -cells were considered alive, while early apoptotic cells displayed staining for annexin V but not for PI. Late apoptotic cells displayed staining for both annexin V and PI. Fluorescence was measured using a BD fluorescence activated cell sorter (FACS)Canto II flow cytometer. CD4 was stained with anti-mouse antibody conjugated with allophycocyanin-cyanin 7 (APC-Cy7) ( 
Quantitative polymerase chain reaction (qPCR)
Transcriptional expression of murine Bim (#Mm00437796_
and Tgfβ (Mm01178820_m1) was determined by TaqMan. Actin (#4352341E) or glyceraldehyde 3-phosphate dehydrogenase (Gapdh, #4352339E) was measured as endogenous control. For human samples, BCL-2 (#Hs00608023_m1), BCL-XL (#Hs00236329_m1), BMF (Hs00372937_m1) and BIM (#Hs01083836_m1) were used. Actin (#4310881E) or GAPDH (#4326317E) was measured as endogenous control (Applied Biosystems, Carlsbad, CA, USA, respectively). Relative mRNA expression was calculated using the Ct method. All samples were analysed as triplicates.
Murine spontaneous colitis model and treatment with BCL-2 inhibitors
Wild-type (WT) mice (Jackson Laboratories, Bar Harbor, ME, USA), B.6129P2-IL-10 tm1Cgn /J (Il10 -/-; Jackson Laboratories) and B.6129P2-Il10 tm1Cgn /J × B6.129-Bcl2l11 tm1.1Ast /J (Il10 -/-× Bim -/-) mice weighing 25-30 g were used. A-1211212 (AbbVie) was applied by oral gavage (p.o., 3, 10, 30, 100 mg/kg/day) dissolved in 30 % polyethylene glycol 400, 60 % phosal PG 50 and 10 % ethanol. ABT-737 was injected intraperitoneally (i.p., 50 mg/kg/day) dissolved in polyethylene glycol, Tween 80, dextrose solution and DMSO. Animals were killed on day 14 of treatment.
Assessment of colonoscopy and histological score in mice
Animals were anaesthetized with isoflurane and examined with the Tele Pack Pal 20043020 (Karl Storz Endoskope, Tuttlingen, Germany). Mice were scored according to the murine endoscopic index of colitis severity (MEICS), as described previously 28. For histological analysis, both colon and small bowel were resected and scored as described 29,30. 
Isolation and culture of murine primary cells
For haematological analyses, murine whole blood was collected in ethylenediamine tetraacetic acid (EDTA)-treated tubes (367525; BD Vacutainer). Analyses were performed with an ADVIA 2120 flow cytometer (Siemens, Munich, Germany). For mass cytometry of murine PBLs, whole blood was collected in EDTA-treated collection tubes. ACK lysing buffer (1·5 M NH4Cl, 100 mM KHCO3, 10 mM Triplex111, pH 7.2) was used.
Splenocytes were isolated using the gentleMACS octo dissociator (130-095-937; Miltenyi Biotech, programme m_spleen 03) and gentleMACS C tubes (130-093-237; Miltenyi Biotech) containing 10 ml ACK lysing buffer. Splenocytes were passed over a 70 μm mesh filter.
For isolation of the lamina propria mononuclear cells (LPMNCs), 10 cm of the small bowel was resected and cut into small pieces. Five ml of a digestive enzyme complex containing collagenase V (C9263-1G; Sigma), collagenase D (11088882001; Roche, Basel, Switzerland), dispase (17105-041; Gibco), DNase (10104159001; Roche) and RPMI medium (21875-034; Gibco) with 10 % FCS was incubated with the small bowel for 30 min at 37 °C. Suspension was vortexed and passed through a 70 μm mesh filter.
Murine CD4 + CD62L + cells from spleen were isolated with the T Cell Isolation Kit II (130-093-227; Miltenyi Biotech). For cell culture, a well plate was coated 24 h before the experiment with anti-CD3 (2 µg/ml, 130-092-973; Miltenyi Biotech). Cells were cultivated in media containing IL-2 (4 ng/ml, 402-ML-020/CF; R&D Systems, Minneapolis, MA, USA) and anti-CD28 (2 µg/ml, 130-093-182; Miltenyi Biotech). ABT-737 (1 μM − 1 × 10 -4 μM) and 6-MP (5 μM − 5 × 10 -4 μM, final concentration each) or vehicle was added for 5 days (37 °C, 5 % CO 2 ).
Myeloperoxidase (MPO) activity assay
Both colon and small bowel specimens were homogenized in 50 mM phosphate buffer containing 0·5% hexadecyltrimethylammonium bromide (H-5882; Sigma) with the gentleMACS octo dissociator (130-095-937; Miltenyi Biotech, programme MPO). After three freeze-and-thaw cycles, homogenates were centrifuged for 10 min at maximum speed; 20 ml of the supernatant were transferred to a 96-well plate in duplicate and mixed with 280 µl of 0·02% dianisidine (in 50 mM phosphate buffer and 0·0005% H 2 O 2 , D-3252; Sigma). Absorbance was measured at 460 nm after 20 or 60 min for samples from Il10 -/-and WT mice, respectively. Protein concentration of the supernatant was determined by the BCA Protein Assay Kit (23252; Thermo Fisher Scientific). MPO activity was calculated as mean absorbance/incubation time/protein content.
Statistical analyses
As indicated in the figure legends, statistical analysis was performed using one-way analysis of variance (anova), all pairwise multiple comparison procedures or KruskalWallis tests to test comparisons among multiple groups. Two-tailed Student's t-tests were used for comparisons between two groups. Sigmaplot version 13 (Systat Software, Inc., San Jose, CA, USA) was used. All data were expressed as the means ± standard deviation (s.d.). Differences were considered significant at a P-value of < 0·05 and highly significant at a P-value of < 0·01 and P-value of < 0·001.
Results
BCL-2 family expression does not predict AZA treatment response in IBD
First, we determined whether the mRNA expression pattern of BCL-2 family members could be used to predict the response to AZA treatment in IBD patients. For NGS analysis, blood samples were collected from patients with sustained remission (successfully treated patients, n = 3) or refractory to treatment (primary non-responders, n = 3, Supporting information, Table S1 ). Following NGS analysis, we determined similar expression of 36 members of the BCL-2 family in patients with remission compared to patients refractory to treatment (P > 0·05 each, Table 1 ). To confirm the results from NGS, we performed qPCR from 23 patients in remission, 18 refractory patients and six healthy controls. Further, blood samples were collected before AZA medication therapy and after the outcome. We determined similar expression levels of BCL-XL, BCL-2, BMF and BIM in patients upon AZA medication therapy with remission compared to patients refractory to treatment (Supporting information, Figs S2-S5). mRNA expression was not correlated with the MTWAI and did not change over time, indicating that the expression of BCL-2 family members cannot predict AZA treatment response in IBD.
BCL-2 family inhibitors, but not 6-MP, induce T cell apoptosis in patients treated with AZA
Next, we determined whether the reduction of lymphocyte counts in IBD patients upon AZA treatment is increased by BCL-2 family inhibitors in vitro. Flow cytometry was performed to quantify the number of viable and apoptotic CD4 + T cells upon treatment with the AZA metabolite 6-MP (5 µM) and the BCL-2 family inhibitor ABT-737 (1 µM) applied for 5 days. In healthy controls, the relative number of early and late apoptotic cells was increased significantly upon 6-MP treatment in vitro compared to vehicle (38·1 ± 5·7 versus 22·5 ± 1·8%, $ P < 0·039, Fig. 1a ). The number of apoptotic cells was also increased significantly upon ABT-737 treatment (40·5 ± 7·2%, $ P < 0·028, Fig. 1a ) and the combined treatment with 6-MP and ABT-737 compared to vehicle (56·3 ± 17·1%, *P < 0·05, Fig. 1a ). The number of apoptotic CD4 + T cells was also increased significantly upon combined treatment compared to 6-MP and ABT-737 treatment alone ( $ P < 0·023 and $ P < 0·032, respectively, Fig. 1a ).
In contrast, the relative number of early and late apoptotic CD4 + T cells from IBD patients treated with AZA remained unchanged upon 6-MP stimulation compared to controls (21·1 ± 0·7% versus 25·6 ± 7·4%, Fig. 1a ). The number of apoptotic cells was increased significantly upon ABT-737 treatment (35·3 ± 8·1%, $$ P < 0·040, Fig.  1a ) and the combined treatment (36·7 ± 6·3%, *P < 0·05, Fig. 1a ) compared to vehicle. The number of apoptotic CD4 + T cells was increased significantly upon combined treatment compared to 6-MP treatment alone ( $$ P < 0·045, Fig. 1a ).
The number of apoptotic CD4 + T cells following 6-MP treatment was increased significantly in healthy controls compared to IBD patients treated with AZA ( # P = 0·004, t-test, Fig. 1a ) and the combined treatment with 6-MP and ABT-737 ( # P = 0·011, t-test, Fig. 1a ). The ratio between apoptotic and non-apoptotic CD4 + T cells in the presence of 6-MP or vehicle was decreased significantly in IBD patients receiving AZA compared to healthy controls (1·21 ± 0·32% versus 1·69 ± 0·28%, n = 9 and 6, respectively, *P < 0·05, Supporting information, Fig.  S6A ).
Next, we analysed the effects of these agents on the expression of BCL-2 family members. We determined a significant decrease in BCL-XL expression in CD4 + T cells from healthy controls following 6-MP stimulation compared to vehicle (0·69 ± 0·12 versus 1·00 ± 0·02, n = 3, respectively, P = 0·01, Supporting information, Fig. S6B ). In CD4 + T cells isolated from IBD patients treated with AZA at the time of medical examination, BCL-XL gene expression remained unchanged upon 6-MP treatment in vitro after 5 days compared to vehicle (1·00 ± 0·16 versus 1·00 ± 0·00, n = 8 and 7, respectively, Fig. 1b ). BCL-XL was decreased upon treatment with the BCL-2 family inhibitors ABT-737, ABT-199 and ABT-263 (0·62·3 ± 0·29, 0·80·3 ± 0·14, n = 8 and 0·62·3 ± 0·25, n = 5; respectively, Fig. 1b ) with a significant difference for ABT-737 and ABT-263 (*P < 0·05 each, Fig. 1b) . BCL-XL was also decreased significantly upon combined treatment of 6-MP and ABT-263 (0·59 ± 0·19, n = 5, *P < 0·05, Fig. 1b ). No significant difference was determined between ABT-263 and cotreatments. Similarly, BCL-2 remained unchanged upon 6-MP stimulation, but was decreased in the presence of the BCL-2 inhibitors (Supporting information, Fig.  S6C , not significant).
BCL-2 family inhibitors initiate cell death in CD4 + T cells from IBD patients refractory to AZA
Next, we determined whether the amount of CD4 + T cells from IBD patients refractory to AZA can be decreased further upon combined treatment with 6-MP and the Normalized counts ± standard deviation for inflammatory bowel disease (IBD) patients with a primary non-response to azathioprine (AZA) (column two) and patients successfully treated with AZA (third column). P-values (P > 0·05 each, t-test). For more information on the NGS, please visit ArrayExpress database using the accession number: E-MTAB-6739. https://www.ebi.ac.uk/arrayexpress/ experiments/E-MTAB-6739/ BCL-2 family inhibitor ABT-737. Blood was drawn from three IBD patients treated with AZA at the time of medical examination, while a considerable resistance to treatment was indicated (Supporting information, Table S1 ). In CD4 + T cells from three IBD patients refractory to AZA, the number of early and late apoptotic cells was increased upon 6-MP treatment compared to vehicle (36·6 ± 14·1% versus 23·2 ± 12·6%, n = 3, respectively, Fig. 2 ). The number of apoptotic CD4 + T cells was increased further upon treatment with ABT-737 (61·3 ± 21·8%, n = 3, Fig. 2 ) or the combined treatment (68·1 ± 14·6%, n = 3, P = 0·055, Fig. 2 ), suggesting that inhibition of BCL-2 initiated cell death in CD4 + T cells from patients refractory to AZA.
Additionally, we determined whether cell survival can be also decreased upon combined treatment in murine CD4 + CD62L + splenocytes. Cell death also increased in a dose-dependent manner in splenocytes upon 6-MP treatment (Supporting information, Fig. S7A ). As 6-MP was less effective in cells isolated from BALB/c mice compared to B6 mice, we determined Bcl-xL in CD4 + CD62L + splenocytes and found increased expression in BALB/c mice compared to B6 mice (P = 0·057, t-test, Supporting information, Fig. S7B ). Cells isolated from BALB/c mice and B6 mice were used for combined treatment experiments. In BALB/c mice, apoptosis in splenocytes was further increased upon the combined treatment with 6-MP and ABT-737 compared to treatment with a single compound or vehicle (Supporting information, Fig. S7C ), confirming the results obtained with human T cells. In B6 mice, apoptosis in splenocytes upon 6-MP or combined treatment was increased significantly compared to vehicle [*P < 0·05, standard error of the mean (s.e.m.)], Supporting information, Fig. S7C ). 
A-1211212 is detected in blood and intestine following oral gavage in mice
The broad range BCL-2 inhibitor ABT-737, which inhibits BCL-2, BCL-XL and BCL-ω, triggers undesirable side effects, including lymphopenia. To reduce adverse side effects, we determined the impact of the BCL-2 specific inhibitor A-1211212 on mucosal inflammation using the Il10 -/-mouse model of spontaneous colitis. A calculated dose of 3, 10, 30 and 100 mg/kg/day was applied by oral gavage for 14 days. Peripheral blood, intestinal epithelial cells (IECs) and whole colon tissue of mice were harvested to confirm the accumulation of A-1211212 in these samples. Following 14 days of treatment, mass spectrometric (MS) analysis detected A-1211212 in sera in a dosedependent manner (0·01 ± 0·00, 0·29 ± 0·09, 0·51 ± 0·24, 0·81 ± 0·13, 1·69 ± 0·01 μg/ml for vehicle, 3, 10, 30 and 100 mg/kg/day, n = 2, respectively). MS analysis also detected A-1211212 in intestinal mucosa in a dose-dependent manner (1·7, 0·3, 20·4 and 42·1 μg/g for vehicle, 3, 30 and 100 mg/kg/day, n = 1, respectively). Less A-1211212 was detected in IECs (< 0·1, 0·3, 1·1 and 1·2 μg/g for vehicle, 3, 10 and 30 mg/kg/day, n = 1, respectively).
A-1211212 ameliorates spontaneous colitis
We then determined the influence of A-1211212 and the broad range inhibitor ABT-737 on mucosal inflammation. Externally, Il10 -/-mice showed a clearly visible rectal prolapse at the beginning of the experiment that was associated with cryptitis and a massive lymphocyte influx into the intestinal mucosa, as determined by haematoxylin and eosin (H&E) staining (Supporting information, Fig.   S8 ). Macroscopic mucosal damage was assessed by miniendoscopy. Mice received either A-1211212 or vehicle, or ABT-737 or vehicle over 14 days. WT mice showed unchanged MEICS regardless of treatment (Fig. 3b) . Il10 -/-mice receiving vehicle displayed an opaque mucosa and altered vascular pattern on day 14 (MEICS 4·6 ± 0·7 and 6·0 ± 2·12 for A-1211212 and ABT-737, n = 8 and 6, respectively, Fig. 3b ). Prominent thickening of the colon and thin faeces were observed and the diseased regions presented mucosal bleeding frequently. During treatment with both A-1211212 and ABT-737, inflammation was ameliorated compared to vehicle-receiving mice. Il10 -/-mice treated with both A-1211212 and ABT-737 had a transparent mucosa with a regular vascular pattern and solid faeces were visible (MEICS 1·3 ± 0·6 and 3·7 ± 1·3 for 10 mg/kg/day A-1211212 and ABT-737, n = 5 and 6, respectively, Fig. 3b ). Microscopic mucosal damage was assessed by histological score. Mice received either A-1211212 (3, 10, 30, 100 mg/kg/day) or vehicle, or ABT-737 (50 mg/kg/day), or vehicle over 14 days. WT mice showed an unchanged histological score regardless of treatment (Fig. 4b) . The histological score of Il10 -/-mice upon treatment with A-1211212 or ABT-737 was significantly lower compared to vehicle-treated mice in small bowel (2·17 ± 0·76 and 3·84 ± 0·28 for 30 mg/kg/day A-1211212 and vehicle, n = 7 and 10, respectively, ***P < 0·001, Fig. 4b ) and colon (2·36 ± 0·48 and 4·17 ± 0·54 for 30 mg/kg/day A-1211212 and vehicle, n = 7 and 10, respectively **P < 0·01, Supporting information, Fig. S9 ). Il10 -/-mice also presented less lymphocyte influx into the thickened lamina propria (white arrows, Fig. 4a ). In summary, BCL-2 To quantify the formation of reactive oxygen species, we performed MPO activity assay. In contrast to WT mice, Il10 -/-mice showed considerably enhanced MPO activity in both small bowel and colon (Fig. 5a,b) . Compared to vehicle-treated mice, A-1211212 treatment decreased MPO activity in a dose-dependent manner in both small bowel and colon in Il10 -/-mice (47·08 ± 28·52 min -1 g -1 and 162·56 ± 141·25 min -1 g -1 for 100 mg/kg/day A-1211212 and vehicle, n = 8 and 8, respectively, *P < 0·05, Fig.  5a ).
We determined gene expression of proinflammatory cytokines in whole mucosal tissue in WT and Il10 -/-mice upon A-1211212 treatment. In WT, expression of Tnf, Il1β, Ifnγ, Mcp1 and Tgfβ was not regulated in a dosedependent manner (not shown). We determined then whether the ameliorated colitis in Il10 -/-mice upon A-1211212 was associated with a decrease in proinflammatory cytokines. At day 14, Tnf gene expression was decreased significantly upon administration of 30 mg/kg/ day A-1211212 compared to vehicle (0·46 ± 0·21 versus 1·00 ± 0·24, n = 7 and 8, respectively, *P < 0·05, Fig. 6a ). Il1β was decreased significantly upon treatment with 10 mg/kg/day A-1211212 compared to vehicle (0·41 ± 0·23 versus 1·00 ± 0·30, n = 7 and 8, respectively, *P < 0·05, Fig. 6a) . Ifnγ was decreased significantly upon treatment with 100 mg/kg/day A-1211212 compared to vehicle (0·57 ± 0·19 versus 1·00 ± 0·15, n = 5 and 8, respectively, *P < 0·05, Fig. 6a ). Mcp1 was decreased significantly upon treatment with 100 mg/kg/day A-1211212 compared to vehicle (0·43 ± 0·25 versus 1·00 ± 0·63, n = 7 and 10, respectively, *P < 0·05, Fig. 6a ). In contrast, Tgfβ increased in a dose-dependent manner upon treatment with A-1211212 compared to vehicle (2·86 ± 2·92 versus 
Il10 -/-WT
1·00 ± 0·29 for 100 mg/kg/day A-1211212 and vehicle, n = 9 and 10, respectively, Fig. 6b ).
A-1211212 shows platelet-sparing features, but shifts lymphocyte populations in vivo
Haematological analyses were performed in WT mice and in the Il10 -/-model of spontaneous colitis to determine whether the increase in number of apoptotic cells upon A-1211212 treatment was associated with a shift in cell populations. Erythrocyte fraction was not affected in WT mice and Il10 -/-mice after 14 days of p.o. gavage of A-1211212 or i.p. injection of ABT-737 when compared to vehicle-receiving controls ( Table 2 ). The platelet fraction remained unchanged upon A-1211212 treatment, but was decreased significantly following ABT-737 administration when compared to vehicle-receiving controls (**P = 0·005, t-test, Table 2 ). The lymphocyte fraction was decreased significantly in WT and Il10 -/-mice after 
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14 daily administrations of 100 mg/kg/day A-1211212 or 50 mg/kg/day ABT-737 when compared to vehicle-receiving controls (*P < 0·05, anova, Table 2 ). The absolute number of lymphocytes was decreased significantly in WT mice upon administration of 100 mg/kg/day A-1211212 compared to controls (0·39 ± 0·04 × 10 3 cells/μl, n = 5 versus 2·23 ± 0·80 × 10 3 cells/μl, n = 5, respectively, t-test, **P = 0·008). The absolute number of lymphocytes was also decreased significantly in Il10 -/-mice upon administration of 100 mg/kg/day A-1211212 compared to controls (0·41 ± 0·31 × 10 3 cells/μl, n = 6 versus 1·80 ± 0·99 × 10 3 cells/μl, n = 8, respectively, t-test, **P = 0·003) and administration of 50 mg/kg/day ABT-737 compared to controls (0·49 ± 0·08 × 10 3 cells/μl, n = 3 versus 1·17 ± 0·40 × 10 3 cells/μl, n = 3, respectively, t-test, *P < 0·05). As inhibition of BCL-2 by ABT-737 is mediated by displacing the pro-apoptotic factor BIM, we also applied ABT-737 to Il10 -/-× Bim -/-mice. The fraction of lymphocytes in these mice was unaltered upon ABT-737 treatment (Table 2 ) and the absolute number of lymphocytes remained unchanged, confirming that BIM is required for the protective effect of ABT-737. The monocyte fraction was decreased in Il10 -/-mice after 14 daily administrations of A-1211212 or ABT-737 when compared to vehicle-receiving controls ( Table 2 ). The granulocyte fraction was increased in Il10 -/-mice after 14 daily administrations of A-1211212 and was increased significantly upon ABT-737 treatment (**P = 0·002, t-test, Table 2 ). In Il10 -/-× Bim -/-mice, the fraction of granulocytes was unaltered upon ABT-737 administration and the absolute number of granulocytes remained unchanged.
The BCL-2 inhibitor significantly decreases the amount of CD8 + T cells
CD4 + and CD8 + splenocytes from WT and colitic Il10 -/-mice were analysed by flow cytometry. In WT mice, a significant decrease in CD8 + T cells following treatment with A-1211212 compared to vehicle-receiving controls was determined (6·5 ± 1·9% versus 14·5 ± 4·3% for 30 mg/ kg/day A-1211212 and vehicle, n = 4 and 7, respectively, **P < 0·01, anova, Fig. 7) . Similarly to the results obtained from WT mice, we determined a significant decrease in CD8 + T cells following treatment with A-1211212 compared to vehicle-receiving controls (4·0 ± 1·3% versus 11·7 ± 3·0% for 30 mg/kg/day A-1211212 and vehicle, n = 5 and 5, respectively, **P < 0·01, anova, Fig. 7) .
Additionally, we determined the CD8 + T cell population in PBL in an individual measurement by mass cytometry. Confirmative to flow cytometry, the proportion of CD8 + T cells was decreased upon A-1211212 (Supporting information, Fig. S10A,B) . The proportion of central memory T cells was decreased upon A-1211212 treatment compared to vehicle-receiving controls [CD45 + , CD19 -, B220 -, T cell receptor (TCR)-β + , CD3 + , CD8 + , CD44 + CD62L + , Supporting information, Fig. S10C ).
Discussion
In accordance with previous reports 11, our results show that the expression pattern of BCL-2 family members in CD4 + T cells is changed upon treatment with the AZA metabolite 6-MP. Nonetheless, transcriptome analysis using NGS indicates that the response to AZA treatment in IBD patients cannot be estimated from mRNA expression was decreased significantly upon ABT-737 when compared to vehicle-receiving controls, n as indicated, error bars = standard deviation (s.d.). Statistics for mice upon A-1211212 were was performed using analysis of variance (anova) on ranks (Holm-Sidak method). Statistics for mice upon ABT-737 were performed using t-test, *P < 0·05, **P < 0·01. Black arrows with a star indicate a significant difference, grey arrows indicate a trend. Bim = B cell lymphoma 2 interacting mediator of cell death; IBD = inflammatory bowel disease; Il = interleukin. levels of BCL-2 family members. Although refractory patients and patients in remission were chosen carefully for this study, treatment duration, medication therapy prior to the study and co-medication during AZA treatment was variable for the benefit of patients. However, given the highly similar expression levels of BCL-2 family members in both groups over time, a predictive value seems unlikely. 6-MP therapy is unable to rescue IBD patients resistant to AZA treatment, evidencing a pressing need for alternative therapies limiting lymphocyte lifespan in these patients. We could confirm previous results showing that 6-MP is reducing the number of CD4 + lymphocytes in vitro in healthy controls not receiving AZA prior to blood collection. In contrast, reduction is limited in IBD patients already receiving AZA. It is well established that dysregulated apoptosis of activated lymphocytes driven by increased anti-apoptotic BCL-2 and BCL-XL contributes to the pathogenesis of IBD 1, 4, 6, 31, 32 . Consequently, our results show that the BCL-2 inhibitors ABT-737, ABT-199 and ABT-263 limit the persistence of human CD4 + lymphocytes in IBD patients receiving AZA prior to blood collection. Further, ABT-737 was shown to limit the persistence of human CD4 + lymphocytes in IBD patients refractory to AZA treatment. Similar results were obtained in previous studies using different BCL-2 inhibitors in various inflammatory conditions characterized by the uncontrolled proliferation of lymphocytes; BCL-2 inhibitors were efficacious in reducing accumulated lymphocytes in murine models of autoimmune diseases 22, arthritis 23 and lupus 24, and suppressed allogeneic T and B cell responses after skin transplantation in vitro and in vivo 33. A recent report assessing the effects of BCL-2 inhibitors in steroid-insensitive airway inflammation showed that BCL-2 inhibitors ameliorate corticosteroid-resistant airway inflammation 34. Increased BCL-2 was found to be responsible for the persistence of granulocytes in bronchoalveolar lavage fluid after allergic challenge. Notably, BCL-2 inhibitors were more efficient than steroids in inducing granulocyte apoptosis in cells from patients with severe asthma 34. One-way analysis of variance (anova). All pairwise multiple comparison procedures (Dunn's method), *P < 0·05, **P < 0·01, ***P < 0·001. In our previous work, we showed that the broad range BCL-2 inhibitor ABT-737 ameliorates inflammation in both the murine model of DSS-induced acute colitis and the Il10 -/-model of spontaneous colitis 26. However, this effect on inflammation was accompanied by lymphopenia due to ABT-737-mediated inhibition of BCL-2, BCL-XL and BCL-ω 17,18. Inhibition of BCL-XL may be responsible for the reduction of platelet lifespan and the observed thrombocytopenia. As a consequence, in the present study we administered the newly developed BCL-2 selective pro-apoptotic compound A-1211212 to the Il10 -/-model of spontaneous colitis to avoid adverse side effects. A-1211212 is a BH3-only mimetic that shows a potent action against various transformed cells, while exhibiting minimal toxicity toward normal cells. Similarly to ABT-737, the specific BCL-2 inhibitor A-1211212 was detected in peripheral blood, colon tissue and IECs following oral gavage. In contrast to ABT-737, we did not observe thrombocytopenia upon A-1211212 treatment. However, similarly to ABT-737, A-1211212 diminished proportions of CD8 + and central memory T cells accompanied by a decrease in Tnf, Ifnγ, Mcp1 and Il1β gene expression. Naive T cell survival is mediated by MCL-1 and BCL-2 35. Consequently, CD4 + naive T cells escape apoptosis in the presence of A-1211212, which is not inhibiting MCL-1. A-1211212 alters the colonic mucosa positively at both macroscopic and microscopic levels, while ameliorating intestinal inflammation in the Il10 -/-model of spontaneous colitis, as shown by MEICS and histological score. Inactivation of BCL-2 is key for BIM to bind directly to pro-apoptotic BAX and BAK in order to initiate apoptosis 36. As inhibition of BCL-2 is also mediated by BIM, we administered A-1211212 to Il10 -/-× Bim -/-mice upon spontaneous colitis. Interestingly, colitis in mice lacking Bim was not ameliorated by A-1211212 treatment confirming the crucial role of this factor in the pharmacological inhibition of BCL-2.
Adjusting the balance between activated and regulatory lymphocyte populations through the inhibition of autoreactive lymphocytes may represent a promising novel therapeutic strategy for CD patients. Our results point to a potential use of the BCL-2 selective, platelet-sparing inhibitor A-1211212 as a new therapeutic drug for the treatment of intestinal inflammation, particularly for IBD patients refractory to AZA treatment.
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